Across TCGA pan-cancer cohorts, IFNA8 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IFNA8 data layer compared with 17 for mass-spec protein.
The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher IFNA8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IFNA8 expression acts as an unfavorable survival marker.
CESC, LUAD, and SARC are the cancer types where IFNA8 Mutation most reproducibly stratifies survival.